XNAS · Healthcare · Biotechnology
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | — | -0.05 | — | $0 | — | +25.66% | -0.69% | — |
| 2026-03-25 | Q4 2025 | — | -0.05 | — | $0 | — | +7.72% | +1.79% | +1.49% |
| 2025-11-12 | Q3 2025 |
| — |
| -0.04 |
| — |
| $0 |
| — |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | — | -0.04 | — | $0 | — | +0.00% | -14.00% | -9.00% |
Showing last 4 quarters.